Omalizumab (marketed as Xolair) is a humanized monoclonal antibody (IgG1 kappa) that binds selectively to immunoglobulin E (IgE) and is indicated for the treatment of severe allergic asthma [5]. The gene discussed is IGHE; the disease is allergic asthma.